Table 4.
Detection performance of MRI vs. US for incidence rates of 3% (baseline), 2% and 1%. Calculations are based on the Markov simulation over a lifetime horizon for a cohort of 1,000 patients.
| Annual incidence of HCC | Strategy | Number of patients diagnosed at BCLC 0 stage | Number of patients diagnosed at BCLC A stage | Number of patients diagnosed at BCLC B, C or D stage | Total HCC |
|---|---|---|---|---|---|
| 3% | US | 59.7 | 139.8 | 224.9 | 424.4 |
| MRI | 268.4 | 95.3 | 60.7 | 424.4 | |
| 2% | US | 43.4 | 101.5 | 163.3 | 308.2 |
| MRI | 194.9 | 69.2 | 44.1 | 308.2 | |
| 1% | US | 23.7 | 55.4 | 89.2 | 168.3 |
| MRI | 106.4 | 37.8 | 24.1 | 168.3 |
BCLC, Barcelona Clinic Liver Cancer; HCC, hepatocellular carcinoma; MRI, magnetic resonance imaging; US, ultrasound.